Exploring New Strategies in Bladder Cancer
|
|
- Johnathan McCormick
- 5 years ago
- Views:
Transcription
1 Exploring New Strategies in Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, Genitourinary Translational Working Group Co-Director, Signal Transduction Program Smilow Cancer Hospital, Yale University
2
3 MVAC vs Cisplatin Phase III Long-Term Survival Cisplatin MVAC Evaluable years years* 2 9 *9 patients died: 6 of progressive disease/transitional-cell carcinoma (TCC), 1 of a second malignancy/colon cancer, 2 died of other causes (1 patient was lost to follow-up evaluation) MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin Saxman SB, et al. J Clin Oncol. 1997;15(7):
4 Kaplan-Meier Curves for Overall Survival GC, gemcitabine/cisplatin von der Maase H, et al. J Clin Oncol. 2005;23(21): von der Maase, H. et al. J Clin Oncol; 23:
5 Salvage Chemotherapy for Advanced Urothelial Cancer Drug Author N RR (%) PFS (months) OS (months) Ifosfamide Witte Gemcitabine Albers Paclitaxel Vaughn Docetaxel McCaffrey NR 9.0 Pemetrexed Galsky 13 8 NR NR Pemetrexed Sweeney Ixabepilone Dreicer OS, overall survival; PFS, progression-free survival; RR, response rate
6 VFL European Phase III Trial Overall survival: Intent-to-treat population (N = 370) Survival Distribution Function VFL + BSC BSC VFL + BSC N = 253 BSC N = 117 No. of events No. censored (%) 49 (19.4) 14 (12.0) Median OS (months) (95% Cl) Hazard ratio (95% CI) 6.9 (5.7, 8.0) 0.88 (0.69, 1.12) P value * (4.1, 7.0) BSC, best supportive care; VFL, vinflunine * Stratified log rank test Bellmunt J, et al. J Clin Oncol. 2009;27(27): Overall survival (months)
7 Atezolizumab (MPDL3280A): Phase Ia Study Ongoing dose-expansion phase UBC N = 92 a TNBC Melanoma NSCLC RCC Other tumor types 1. PD-L1 selected 2. Allcomers b 1. PD-L1 selected 2. Allcomers All-comers 1. Allcomers 2. PD-L1 selected 1. Allcomers 2. PD-L1 selected 1. PD-L1 selected 2. Allcomers Atezolizumab (MPDL3280A) administered IV Q3W 15 mg/kg or 1200 mg flat dose Key eligibility criteria: Measurable disease per RECIST v1.1 ECOG PS 0 or 1 a Safety-evaluable UBC population. b The UBC cohort originally enrolled patients with PD-L1 IC2/3 but was then expanded to include all-comers, primarily recruiting PD-L1 IC0/1 patients. NSCLC, non-small cell lung cancer; RCC, renal-cell carcinoma; TNBC, triple-negative breast cancer; UBC, urothelial bladder cancer Powles T, et al. J Clin Oncol. 2014;32(Suppl): Abstract Powles T, et al. Nature. 2014;515(7528): Bellmunt J, et al. Ann Oncol. 2014;25(Suppl 4): Abstract Xiao Y, et al. J Immunother Cancer. 2014; 2(Suppl 3): P131. Kim J, et al. J Clin Oncol. 2015;33(suppl): Abstract 297. Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
8
9 IHC Characteristics of Prescreened Patients: PD-L1 Expression in the UBC Tumor Microenvironment The SP142 assay measures PD-L1 expression based on 4 IHC scoring levels a This assay is optimized for detection of PD-L1 expression in both tumor cells (TC) and tumor infiltrating immune cells (IC) In UBC, prevalence of PD-L1 on TC is low, 1,2 and patients who express PD-L1 on TC are captured within IC cutoffs In UBC, PD-L1 expression on IC is correlated with response, 1,2 while TC expression is not predictive PD-L1 expression is associated with atezolizumab clinical activity in other cancers, including NSCLC 3-6 PD-L1 prevalence in UBC b IHC level (N = 205) IC scored as PD-L1+, n (%) IC3 18 (9%) IC2 37 (18%) IC1 89 (43%) IC0 61 (30%) PD-L1 expression in IC a IC scoring criteria: IC3: 10% of IC PD-L1+; IC2: 5% but < 10% of IC PD-L1+; IC1: 1% but < 5% of IC PD-L1+; IC0: < 1% of IC PD-L1+. b Based on staining of archival tumor tissue from patients prescreened in atezolizumab Phase Ia study. IHC, immunehistochemical 1. Bellmunt J, et al. Ann Oncol. 2014;25(Suppl 4): Abstract Powles T, et al. Nature. 2014;515(7528): Spira A, et al. J Clin Oncol. 2015;33(suppl): Abstract Horn L, et al. J Clin Oncol. 2015;33(suppl): Abstract Liu S, et al. J Clin Oncol. 2015;33(suppl): Abstract Spigel D, et al. J Clin Oncol. 2015;33(suppl): Abstract Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
10 Atezolizumab (MPDL3280A): Baseline Characteristics in UBC (Safety Evaluable) Characteristic Patients N = 92 a Median age, y (range) 66 (36-89) Male, n (%) 69 (75%) ECOG PS, n (%) 0 37 (40%) 1 55 (60%) Site of primary tumor Bladder 73 (79%) Renal pelvis 5 (5%) Ureter 9 (10%) Urethra 5 (5%) Site of metastases at baseline, n (%) Visceral b 73 (79%) Liver 34 (37%) Characteristic Poor prognostic factors included visceral mets, low hemoglobin levels, ECOG PS 1 and short time ( 3 months) from prior chemo 1,2 a Safety-evaluable patients received at least 1 dose of atezolizumab. b Includes lung, liver, non-lymph or soft tissue. c n = 89. Data cutoff, Dec 2, GFR, glomerular filtration rate; mets, metastases Patients N = 92 a Prior treatments, n (%) Cystectomy or nephroureterectomy 56 (61%) Platinum-based chemotherapy 86 (94%) Cisplatin-based 69 (75%) Carboplatin-based 35 (38%) 2 prior systemic therapies (metastatic) 66 (72%) 3 months from last chemotherapy 37 (42%) c Hemoglobin levels < 10 g/dl 16 (17%) GFR < 60 ml/min 38 (41%) 1. Bellmunt J, et al. J Clin Oncol. 2010;28(11): Pond GR, et al. BJU Int. 2014;113(5b):E Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
11 Atezolizumab (MPDL3280A): Baseline Characteristics in UBC (Safety Evaluable) Characteristic Patients N = 92 a Median age, y (range) 66 (36-89) Male, n (%) 69 (75%) ECOG PS, n (%) 0 37 (40%) 1 55 (60%) Site of primary tumor Bladder 73 (79%) Renal pelvis 5 (5%) Ureter 9 (10%) Urethra 5 (5%) Site of metastases at baseline, n (%) Visceral b 73 (79%) Liver 34 (37%) Characteristic Patients N = 92 a Prior treatments, n (%) Cystectomy or nephroureterectomy 56 (61%) Platinum-based chemotherapy 86 (94%) Cisplatin-based 69 (75%) Carboplatin-based 35 (38%) 2 prior systemic therapies (metastatic) 66 (72%) 3 months from last chemotherapy 37 (42%) c Hemoglobin levels < 10 g/dl 16 (17%) GFR < 60 ml/min 38 (41%) Poor prognostic factors included visceral mets, low hemoglobin levels, ECOG PS 1 and short time ( 3 months) from prior chemo 1,2 a Safety-evaluable patients received at least 1 dose of atezolizumab. b Includes lung, liver, non-lymph or soft tissue. c n = 89. Data cutoff, Dec 2, GFR, glomerular filtration rate; mets, metastases 1. Bellmunt J, et al. J Clin Oncol. 2010;28(11): Pond GR, et al. BJU Int. 2014;113(5b):E Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
12 Atezolizumab (MPDL3280A): Baseline Characteristics in UBC (Safety Evaluable) Characteristic Patients N = 92 a Median age, y (range) 66 (36-89) Male, n (%) 69 (75%) ECOG PS, n (%) 0 37 (40%) 1 55 (60%) Site of primary tumor Bladder 73 (79%) Renal pelvis 5 (5%) Ureter 9 (10%) Urethra 5 (5%) Site of metastases at baseline, n (%) Visceral b 73 (79%) Liver 34 (37%) Characteristic Patients N = 92 a Prior treatments, n (%) Cystectomy or nephroureterectomy 56 (61%) Platinum-based chemotherapy 86 (94%) Cisplatin-based 69 (75%) Carboplatin-based 35 (38%) 2 prior systemic therapies (metastatic) 66 (72%) 3 months from last chemotherapy 37 (42%) c Hemoglobin levels < 10 g/dl 16 (17%) GFR < 60 ml/min 38 (41%) Poor prognostic factors included visceral mets, low hemoglobin levels, ECOG PS 1 and short time ( 3 months) from prior chemo 1,2 a Safety-evaluable patients received at least 1 dose of atezolizumab. b Includes lung, liver, non-lymph or soft tissue. c n = 89. Data cutoff, Dec 2, GFR, glomerular filtration rate; mets, metastases 1. Bellmunt J, et al. J Clin Oncol. 2010;28(11): Pond GR, et al. BJU Int. 2014;113(5b):E Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
13 Atezolizumab (MPDL3280A): Baseline Characteristics in UBC (Safety Evaluable) Characteristic Patients N = 92 a Median age, y (range) 66 (36-89) Male, n (%) 69 (75%) ECOG PS, n (%) 0 37 (40%) 1 55 (60%) Site of primary tumor Bladder 73 (79%) Renal pelvis 5 (5%) Ureter 9 (10%) Urethra 5 (5%) Site of metastases at baseline, n (%) Visceral b 73 (79%) Liver 34 (37%) Characteristic Patients N = 92 a Prior treatments, n (%) Cystectomy or nephroureterectomy 56 (61%) Platinum-based chemotherapy 86 (94%) Cisplatin-based 69 (75%) Carboplatin-based 35 (38%) 2 prior systemic therapies (metastatic) 66 (72%) 3 months from last chemotherapy 37 (42%) c Hemoglobin levels < 10 g/dl 16 (17%) GFR < 60 ml/min 38 (41%) Poor prognostic factors included visceral mets, low hemoglobin levels, ECOG PS 1 and short time ( 3 months) from prior chemo 1,2 a Safety-evaluable patients received at least 1 dose of atezolizumab. b Includes lung, liver, non-lymph or soft tissue. c n = 89. Data cutoff, Dec 2, GFR, glomerular filtration rate; mets, metastases 1. Bellmunt J, et al. J Clin Oncol. 2010;28(11): Pond GR, et al. BJU Int. 2014;113(5b):E Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
14 Atezolizumab (MPDL3280A): Baseline Characteristics in UBC (Safety Evaluable) Characteristic Patients N = 92 a Median age, y (range) 66 (36-89) Male, n (%) 69 (75%) ECOG PS, n (%) 0 37 (40%) 1 55 (60%) Site of primary tumor Bladder 73 (79%) Renal pelvis 5 (5%) Ureter 9 (10%) Urethra 5 (5%) Site of metastases at baseline, n (%) Visceral b 73 (79%) Liver 34 (37%) Characteristic Patients N = 92 a Prior treatments, n (%) Cystectomy or nephroureterectomy 56 (61%) Platinum-based chemotherapy 86 (94%) Cisplatin-based 69 (75%) Carboplatin-based 35 (38%) 2 prior systemic therapies (metastatic) 66 (72%) 3 months from last chemotherapy 37 (42%) c Hemoglobin levels < 10 g/dl 16 (17%) GFR < 60 ml/min 38 (41%) Poor prognostic factors included visceral mets, low hemoglobin levels, ECOG PS 1 and short time ( 3 months) from prior chemo 1,2 a Safety-evaluable patients received at least 1 dose of atezolizumab. b Includes lung, liver, non-lymph or soft tissue. c n = 89. Data cutoff, Dec 2, GFR, glomerular filtration rate; mets, metastases 1. Bellmunt J, et al. J Clin Oncol. 2010;28(11): Pond GR, et al. BJU Int. 2014;113(5b):E Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
15 Atezolizumab (MPDL3280A): Baseline Characteristics in UBC (Safety Evaluable) Characteristic Patients N = 92 a Median age, y (range) 66 (36-89) Male, n (%) 69 (75%) ECOG PS, n (%) 0 37 (40%) 1 55 (60%) Site of primary tumor Bladder 73 (79%) Renal pelvis 5 (5%) Ureter 9 (10%) Urethra 5 (5%) Site of metastases at baseline, n (%) Visceral b 73 (79%) Liver 34 (37%) Characteristic Prior treatments, n (%) Cystectomy or nephroureterectomy Patients N = 92 a 56 (61%) Platinum-based chemotherapy 86 (94%) Cisplatin-based 69 (75%) Carboplatin-based 35 (38%) 2 prior systemic therapies 66 (72%) (metastatic) 3 months from last chemotherapy 37 (42%) c Hemoglobin levels < 10 g/dl 16 (17%) GFR < 60 ml/min 38 (41%) Poor prognostic factors included visceral mets, low hemoglobin levels, ECOG PS 1 and short time ( 3 months) from prior chemo 1,2 a Safety-evaluable patients received at least 1 dose of atezolizumab. b Includes lung, liver, non-lymph or soft tissue. c n = 89. Data cutoff, Dec 2, GFR, glomerular filtration rate; mets, metastases 1. Bellmunt J, et al. J Clin Oncol. 2010;28(11): Pond GR, et al. BJU Int. 2014;113(5b):E Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
16 Atezolizumab (MPDL3280A): Treatment- Related Adverse Events (AEs) in UBC Treatment-related AEs occurring in 5% of patients (all grade) or in 2 patients (grade 3-4) N = 92 a All grade Grade 3-4 b Any AE 60 (65%) 7 (8%) Fatigue 15 (16%) 0 Asthenia 12 (13%) 1 (1%) Nausea 10 (11%) 0 Decreased appetite 9 (10%) 0 Pruritus 9 (10%) 0 Pyrexia 6 (7%) 0 Rash 7 (8%) 0 Diarrhea 5 (5%) 0 Increased AST 2 (2%) 2 (2%) Atezolizumab was generally well tolerated Median safety follow-up was 16+ weeks (range, 3 to 86+ weeks) Median duration of treatment was 3 months (range, 0 to 19 months) No treatment-related deaths 1 discontinuation due to a treatmentrelated AE 5% of patients had a grade 3-4 immunemediated AE per investigator assessment Grade 3 AEs: increased AST (n = 3); increased ALT (n = 2); increased blood bilirubin (n = 1); hypophysitis (n = 1) 37 patients (40%) had a Grade 3-4 AE of any cause c a Safety-evaluable patients received at least 1 dose of atezolizumab. b Additional Gr 3-4 AEs (1% each) included anemia, confusional state, decreased blood phosphorus, hypophysitis, increased ALT, increased GGT and thrombocytopenia. c In addition, 2 grade 5 AEs not related to treatment were seen (acute respiratory failure and alcohol overdose). Data cutoff, Dec 2, Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
17 Atezolizumab (MPDL3280A): ORR in UBC by IC Status PD-L1 IHC n = 87 b IC3 (n = 12) 67% (35%-90%) IC2 (n = 34) 44% (27%-62%) IC1 (n = 26) 19% (7%-39%) IC0 (n = 15) 13% (2%-40%) ORR (95% CI), % a 50% (35, 65) 17% (7, 32) 4 (33%) 5 (15%) CR, n (%) 9 (20%) 4 (33%) 10 (29%) - 5 (19%) (13%) PR, n (%) 14 (30%) 7 (17%) Responses were observed in all PD-L1 subgroups, with higher ORRs associated with higher PD-L1 expression in IC Responders also included patients with visceral metastases at baseline: 38% ORR (95% CI, 21%-56%) in 32 IC2/3 patients and 14% (95% CI, 5%-30%) ORR in 36 IC0/1 patients a Efficacy-evaluable patients with measurable disease at baseline per RECIST v1.1. Responses are investigator assessed (unconfirmed); of 30 unconfirmed responses, 24 have been confirmed by the cutoff date. b 4 IC2/3 patients and 7 IC0/1 patients missing or unevaluable. Data cutoff, Dec 2, CR, complete response; PR, partial response; ORR, overall response rate Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
18 Atezolizumab (MPDL3280A): Duration of Treatment and Response in UBC Patients with UBC and CR or PR as best response Median duration of response (DoR) has not yet been reached in either IC group (range, 0+ to 43 months) Median time to response was 62 days IC2/3 patients: range, 1+ to 10+ months IC0/1 patients: range, 1+ to 7+ months 20 of 30 responding patients had ongoing responses at the time of data cutoff 10 patients have been treated for over 1 year, including 3 retreated following protocol amendment a Discontinuation and ongoing response status markers have no timing implication. 4 patients discontinued treatment after cycle 16 prior to 1 year per original protocol. Responses plotted are investigator assessed and have not all been confirmed by the data cutoff (Dec 2, 2014). Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
19 Atezolizumab (MPDL3280A): Survival in UBC Survival a N = 92 IC2/3 n = 48 IC0/1 n = 44 Median survival follow-up: 14 months (IC2/3) 12 months (IC0/1) PFS Median PFS (range) 6 months (0+ to 18) 1 months (0+ to 14+) Median OS not reached (95% CI, 9.0 mo-ne) 1-y PFS (95% CI) 39% (24-54) 10% (0-21) OS Median OS (range) Not reached (1 to 20+ months) 8 months (1 to 15+ months) IC2/3 IC0/1 + Censored Median OS 7.6 mo (95% CI, 4.7 mo-ne) 1-y survival (95% CI) 57% (41-73) 38% (19-56) PD-L1 IC status appeared to be predictive of benefit from atezolizumab treatment mpfs and 1-year PFS rates were higher in atezolizumab-treated patients with higher PD-L1 IC expression The same association was observed for 1-year OS rates, and median OS for IC2/3 patients was not yet reached Preliminary analysis using SP142 from an independent sample set (n = 110) suggests that PD-L1 IC status is not prognostic for OS in UBC 1 Data cutoff, Dec 2, Reference: 1. Genentech, unpublished data. Petrylak DP, et al. J Clin Oncol. 2015;33(suppl): Abstract 4501.
20 IMvigor210 Cohort 2: Study Design Basis for Accelerated Approval Locally advanced or metastatic urothelial carcinoma Predominantly TCC histology Tumor tissue for PD-L1 testing a Cohort 1 (N = 119) 1L Cisplatin Ineligible Cohort 2 (N = 310) Platinum-treated muc Cohort 1 presented at ASCO Atezolizumab 1200 mg IV q3w until loss of benefit Cohort 2: Specific inclusion criteria Progression during/following platinum (no restrictions on # prior lines of therapy) ECOG PS 0-1 CrCl 30 ml/min Median follow-up: 17.5 months (range, 0.2 to mo) a Patients and investigators blinded to PD-L1 IHC status. Trial Identifier: NCT Co-primary endpoints: ORR (confirmed) per RECIST v1.1 by central review ORR per immune-modified RECIST by investigator Key secondary endpoints: DOR, PFS, OS, safety Key exploratory endpoints: Intratumoral biomarkers (Presented at ASCO ) 1. Balar AV, et al. J Clin Oncol. 2016;34(suppl): Abstract LBA Rosenberg J, et al. J Clin Oncol. 2016;34(suppl): Abstract 104. Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
21 IMvigor210 Cohort 2: Baseline Characteristics Representative of the Greater muc Population Characteristic (safety and efficacy evaluable patients) N = 310 Age, median (range) 66 years (32-91 years) Male 78% PD-L1 status on immune cells (IC): a IC2/3 IC1 IC0 32% 35% 33% Bladder primary tumor site 75% Metastatic sites: visceral b liver lymph node only 78% 31% 14% Creatinine clearance ml/min 35% ECOG PS 1 62% Prior cystectomy or nephroureterectomy 66% Prior regimens (metastatic setting): % 21% 21% a PD-L1 expression on IC was evaluated (VENTANA SP142 IHC assay) based on 3 scoring levels: IC2/3 ( 5%), IC1 ( 1 but <5%), IC0 (<1%). b Defined as liver, lung, bone, or any non-lymph node or soft tissue metastasis. Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
22 Efficacy Responses to Atezolizumab by PD-L1 IC Subgroup IC2/3 n = 100 IC1/2/3 n = 207 All a N = 310 IC1 n = 107 IC0 n = 103 ORR: confirmed IRF RECIST v1.1 (95% CI) 28% (19, 38) 19% (14, 25) 16% (12, 20) 11% (6, 19) 9% (4, 16) CR rate: confirmed IRF RECIST v1.1 (95% CI) 15% (9, 24) 9% (6, 14) 7% (4, 10) 4% (1, 9) 2% (0, 7) Responses were seen in all IC subgroups, but ORR was enriched with higher PD-L1 status Complete responses accounted for nearly half of the observed responses CRs were observed in all PD-L1 subgroups, with the highest rate in IC2/3 patients ORRs per immune-modified RECIST were concordant a Includes 46 patients with missing/unevaluable responses. b CR + PR + SD 24-wk rate per IRF RECIST v1.1. Treated patients had measurable disease at baseline per investigator-assessed RECIST v1.1. Data cutoff: March 14, Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
23 Efficacy Time to Response Patients With CR or PR as Best Response 1 st responses Median follow-up: 17.5 months (range, 0.2 to mo) Months Median time to first response was 2.1 months Range: 1.6 to 8.3 months Median time to CR was 4.2 months Range 2.0 to 13.2 months Additional CRs and PRs were observed with longer follow up 5 PR to CR and 2 SD to PR conversions CR as best response PR as best response First CR/PR Treatment discontinuation b Ongoing response c a Per IRF RECIST v1.1 b Discontinuation symbol does not indicating timing. c No PD or death only. Data cutoff: March 14, Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
24 Evidence of Clinical Benefit In Patients Treated Beyond Progression Subsequent responses to atezolizumab were seen across PD-L1 subgroups, highlighting the potential for benefit through non-classical responses SLD Changed from PD, % Patients Treated Beyond PD With Reduction in Tumor Burden IC2/3 IC1 IC0 Discontinued New lesion In patients treated beyond PD 19% (26/134) had a reduction in tumor burden ( 30% decrease in target lesions) 8% (11/134) achieved PR, CR or SD per IRF RECIST v1.1 post PD Median OS was 11.4 months (all patients) and 16.5 months (IC2/3 patients) 12-month OS was 50% (all patients) and 57% (IC2/3 patients) The safety of atezolizumab was consistent with that in the ITT population Time on Study, weeks Patients without post-pd baseline tumor assessments (n = 29) are not included in Plot. Data cutoff: March 14, PD, progressive disease Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
25 Efficacy Overall Survival Overall Survival All patients + Censored Time, months All patients # at Risk: All pts: Longer OS observed in patients with higher PD-L1 IC status mpfs (2.1 mo per RECIST v1.1; 2.6 mo per imrecist) underscores a disconnect between PFS and OS Subgroup All pts (N = 310) Subgroup All pts (N = 310) 12-mo OS (95% CI) IC2/3 IC0/1 All 50% (40, 60) Median OS (95% CI) IC2/3 IC0/1 All 11.9 mo (9.0, 17.9) 6.7 mo (5.4, 8.0) 31% (24, 37) Median follow-up (range): All Pts: 17.5 mo (0.2 to mo) 7.9 mo (6.7, 9.3) 37% (31, 42) NE, not estimable. Data cutoff: March 14, Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
26 Efficacy Overall Survival Overall Survival All Patients All 2L Patients only + Censored Time, months All patients and 2L only # at Risk: All pts: L only: Longer OS observed in patients with higher PD-L1 IC status 12-mo OS compares favorably with historic estimates of 20% 1 Subgroup All pts (N = 310) 2L only (n = 120) Subgroup All pts (N = 310) 2L only (n = 120) 12-mo OS (95% CI) IC2/3 IC0/1 All 50% (40, 60) 61% (44, 77) Median OS (95% CI) IC2/3 IC0/1 All 11.9 mo (9.0, 17.9) NE (10.9, NE) 6.7 mo (5.4, 8.0) 7.1 mo (5.0, 9.2) 31% (24, 37) 29% (19, 39) Median follow-up (range): All pts: 17.5 mo (0.2 to mo) 2L only: 17.3 mo (0.5 to mo) 7.9 mo (6.7, 9.3) 9.0 mo (7.2, 11.3) 37% (31, 42) 38% (29, 47) NE, not estimable. a 1 prior line of therapy for muc and no (neo)adjuvant therapy. Data cutoff: March 14, Aggarwal R, et al. Clin Genitourin Cancer. 2014;12(5):e Dreicer R, et al. J Clin Oncol. 2016;34(suppl): Abstract 4515.
27 ORR, % TCGA Subtype II Is Associated With Higher ORR n = 73 n = 52 n = 38 n = 36 RECIST v1.1 response PD SD PR CR Gene expression data used to classify IMvigor210 tumor samples recapitulated TCGA subtypes 1,2 Responses occurred in all subtypes, but ORR was significantly higher in luminal II vs other subtypes (P =.0072) Urothelium Luminal 0 I II III IV Luminal Basal Basal TCGA, The Cancer Genome Atlas. Data cutoff: March 14, Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Rosenberg JE, et al. Lancet. 2016;387(10031): Choi W, et al. Nat Rev Urol. 2014;11(7): Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
28 TCGA Subtype II Is Associated With Higher ORR ORR, % n = 73 n = 52 n = 38 n = 36 RECIST v1.1 response PD SD PR CR Gene expression data used to classify IMvigor210 tumor samples recapitulated TCGA subtypes 1,2 Responses occurred in all subtypes, but ORR was significantly higher in luminal II vs other subtypes (P =.0072) What might be the drivers of this subtype-specific response? 0 I II III IV Luminal Basal TCGA, The Cancer Genome Atlas. Data cutoff: March 14, Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Rosenberg JE, et al. Lancet. 2016;387(10031): Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
29 IMvigor210: TCGA Subtype in muc TCGA Subtype Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CDKN2A, cyclin-dependent kinase inhibitor 2A; EGFR, epidermal growth factor receptor; FGFR3, fibroblast growth factor receptor 3; GATA3, GATA-binding protein 3. Data cutoff: March 14, Choi W, et al. Nat Rev Urol. 2014;11(7): Aine M, et al. Sci Rep. 2015;5: Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
30 IMvigor210: TCGA Subtype in muc TCGA Subtype Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CDKN2A, cyclin-dependent kinase inhibitor 2A; EGFR, epidermal growth factor receptor; FGFR3, fibroblast growth factor receptor 3; GATA3, GATA-binding protein 3. Data cutoff: March 14, Choi W, et al. Nat Rev Urol. 2014;11(7): Aine M, et al. Sci Rep. 2015;5: Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
31 IMvigor210: TCGA Subtype in muc TCGA Subtype Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CDKN2A, cyclin-dependent kinase inhibitor 2A; EGFR, epidermal growth factor receptor; FGFR3, fibroblast growth factor receptor 3; GATA3, GATA-binding protein 3. Data cutoff: March 14, Choi W, et al. Nat Rev Urol. 2014;11(7): Aine M, et al. Sci Rep. 2015;5: Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
32 IMvigor210: TCGA Subtype in muc TCGA Subtype Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 Urothelium Luminal Basal Luminal and basal tumors are distinct subtypes with unique histology and gene expression 1-3 CDKN2A, cyclin-dependent kinase inhibitor 2A; EGFR, epidermal growth factor receptor; FGFR3, fibroblast growth factor receptor 3; GATA3, GATA-binding protein 3. Data cutoff: March 14, Choi W, et al. Nat Rev Urol. 2014;11(7): Aine M, et al. Sci Rep. 2015;5: Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
33 IMvigor210: TCGA Subtype in muc TCGA Subtype T eff Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CD8A GZMA GZMB IFNG CXCL9 CXCL10 PRF1 TBX21 Urothelium Luminal Basal Luminal I patients have low T eff gene expression Data cutoff: March 14, Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
34 IMvigor210: TCGA Subtype in muc TCGA Subtype T eff Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CD8A GZMA GZMB IFNG CXCL9 CXCL10 PRF1 TBX21 Urothelium Luminal Basal Luminal I patients have low T eff gene expression In Luminal II patients with disease progression, a trend toward lower baseline T eff expression was seen, compared with Luminal II responders Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
35 IMvigor210: TCGA Subtype in muc TCGA Subtype T eff Stromal Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CD8A GZMA GZMB IFNG CXCL9 CXCL10 PRF1 TBX21 COL4A1 COL4A2 PDGFRB BGN NUAK1 Urothelium Stromal genes were also analyzed Luminal Basal COL4A, collagen type IV α; PDGFRB, platelet-derived growth factor β. Data cutoff: March 14, Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
36 IMvigor210: TCGA Subtype in muc TCGA Subtype T eff Stromal Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CD8A GZMA GZMB IFNG CXCL9 CXCL10 PRF1 TBX21 COL4A1 COL4A2 PDGFRB BGN NUAK1 Urothelium Luminal Basal Subtype II patients tended to have lower stromal gene expression Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
37 IMvigor210: TCGA Subtype in muc TCGA Subtype T eff Stromal Luminal Basal I II III IV Papillary like Squamous Mesenchymal Response IC status TC status FGFR3 CDKN2A KRT5 KRT14 EGFR GATA3 FOXA1 ERBB2 CD8A GZMA GZMB IFNG CXCL9 CXCL10 PRF1 TBX21 COL4A1 COL4A2 PDGFRB BGN NUAK1 Urothelium Luminal Basal Luminal I tumors have low T eff expression Luminal II tumors have high T eff and low stromal gene expression Basal tumors have high T eff and high stromal gene expression Data cutoff: March 14, Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
38 IMvigor210: TCGA Subtype in muc Luminal Basal I II III IV Papillary like Squamous Mesenchymal Immune desert Inflamed Immune suppressed a Response IC status TC status IMvigor210 subtypes have distinct tumor-immune landscapes that reflect responsiveness to atezolizumab Tumor stroma Tumor cells TIL/immune cells Increased responses TIL, tumor-infiltrating lymphocyte. a High myeloid, inflammatory, activated stromal/fibroblast markers. Data cutoff: March 14, Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
39 Mutation Load by FoundationOne and Response muc has a high mutation load and thus potential for neoantigen generation and recognition by the immune system 1-3 Median load was significantly higher in responders vs non-responders This relationship was statistically independent of other predictors of response RECIST v1.1 response Responder Non-responder Mutation Load/MB All (n = 150) I II Luminal III Basal IV Mutation Load/MB IC0/1 IC2/3 1. Lawrence MS, et al. Nature. 2013;499(7457): Cancer Genome Atlas Research Network. Nature. 2014;507(7492): Kandoth C, et al. Nature. 2013;502(7471): Data cutoff: March 14, Rosenberg JE, et al. J Clin Oncol. 2016;34(suppl): Abstract 104.
40 Front-Line Therapy for Urothelial Cancer: Cisplatin-Ineligible Balar AV, et al. J Clin Oncol. 2016;34(suppl): Abstract LBA4500.
41 Efficacy: Change in Tumor Burden Balar AV, et al. J Clin Oncol. 2016;34(suppl): Abstract LBA4500.
42 Study 1108: Dose-Escalation and Dose-Expansion Study in Patients With Advanced Solid Tumors Massard C, et al. J Clin Oncol. 2016;34(suppl): Abstract 4502.
43 Confirmed ORR and DCR12 by PD-L1 Localization Massard C, et al. J Clin Oncol. 2016;34(suppl): Abstract 4502.
44 Study Design Sharma P, et al. J Clin Oncol. 2016;34(suppl): Abstract 4501.
45 Antitumor Activity Sharma P, et al. J Clin Oncol. 2016;34(suppl): Abstract 4501.
46 Progression-Free Survival Sharma P, et al. J Clin Oncol. 2016;34(suppl): Abstract 4501.
47 Overall Survival Sharma P, et al. J Clin Oncol. 2016;34(suppl): Abstract 4501.
48 ASG-22CE (ASG-22ME; Enfortumab Vedotin) in a Phase I Dose Escalation Trial in Patients (Pts) With Metastatic Urothelial Cancer CONCLUSIONS Enfortumab vedotin is well tolerated and shows encouraging anti-tumor activity with 10 PRs (ORR = 30.3%) Enfortumab vedotin shows promising anti-tumor activity in subjects with liver metastases (4/10 = 40%) and those previously treated with checkpoint inhibitors (3/12 = 25%) The ocular AEs experienced with enfortumab vedotin are of low grade and reversible with appropriate management. Preliminary PK profile for the antibody drug conjugate (ADC) reveals a short half-life of 1.5 days with no accumulation between the 1 st and 3 rd doses of cycle 1 FUTURE PLANS Enrollment at 1 and 1.25 mg/kg is ongoing to identify the maximum tolerated dose and a recommended dose for future studies Petrylak DP, et al. J Clin Oncol. 2016;34(suppl): Abstract 4532.
49 Pembrolizumab (MK-3475) Humanized IgG4, High-Affinity, Anti-PD-1 Antibody Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
50 Baseline Characteristics Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
51 Treatment Related Adverse Events Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
52 AEs of Interest Based On Immune Etiology Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
53 Antitumor Activity Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
54 Treatment Exposure and Response Duration Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
55 Survival (Central Radiology Assessment) Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
56 PD-L1 IHC Staining in Bladder Cancer Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
57 Exploratory Predictive Value of PD-L1 Scoring Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
58 Association Between Immune-Related Gene Expression Signatures and Clinical Outcome Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
59 Immune-Related Gene Expression Signatures Identified in Melanoma Patients Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
60 Exploratory Analysis of the Association Between Immune-Related Gene Expression Signatures and Response Plimack ER, et al. J Clin Oncol. 2015;33(suppl): Abstract 4502.
61 Rational for VEGF Blockade in Bladder Cancer Antiangiogenic agents, particularly anti-vegfr-2 monoclonal antibodies (mabs), may be capable of acting as chemosensitizing agents when given in combination with docetaxel, since this effect was demonstrated in mice when an anti-vegfr-2 mab, DC101, was combined with paclitaxel Anti-VEGFR-1 mabs may inhibit metastasis, based on the observed impact of the anti-vegfr-1 mab, MF1, on VEGFR-1- positive circulating hematopoietic progenitor cells in mice
62 Binding of Ramucirumab to VEGFR-2 and Icrucumab to VEGFR-1 Inhibits Subsequent Signaling
63 Expression of VEGFR-2 in Bladder Cancer But Not in Normal Urothelium
64 JCDC: Study Design S C R E E N 1:1:1 R A N D O M I Z E Docetaxel 75 mg/m 2 day 1 of a 21-day cycle N = 44 Docetaxel 75 mg/m 2 day 1 + Ramucirumab 10 mg/kg day 1 of a 21-day cycle N = 46 Docetaxel 75 mg/m 2 day 1 + Icrucumab 12 mg/kg days 1 and 8 of a 21-day cycle N = 49 Treat until disease progression or intolerable toxicity Survival and safety follow-up Primary Endpoint: Progression-free survival (PFS) Secondary Endpoints: Overall survival, objective response rate, duration of response, safety, PK/PD and immunogenicity profile Stratification factors: Visceral metastasis (yes vs. no) Prior antiangiogenic therapy (yes vs. no)
65 Progression-Free Survival Interim Analysis
66 RANGE (Trial I4T-MC-JVDC): Study Design S C R E E N 1:1 R A N D O M I Z E Docetaxel 75 mg/m 2 + Placebo 10 mg/kg I.V. on day 1 of a 21-day cycle N = 262 Docetaxel 75 mg/m 2 + Ramucirumab 10 mg/kg I.V. day 1 of a 21-day cycle N = 262 Oversight by an IDMC Treat until disease progression or intolerable toxicity Primary Objective PFS Key Secondary Objectives OS and ORR Important Inclusion Criteria: Locally advanced or unresectable or metastatic UC and ECOG PS 0 or 1 Progression on or after first-line platinum-based chemotherapy ( 14 months; or 24 months if prior treatment with one immune checkpoint inhibitor) Key Exclusion Criteria: Hemoglobin < 9 g/dl Uncontrolled bleeding or thrombotic disorder Known untreated brain metastasis Petrylak DP, et al. J Clin Oncol. 2015;33(suppl 7): Abstract 295.
67 Phase I Trial Pembrolizumab + Ramucirumab in Metastatic Cancer PI Overall Roy Herbst Bladder Petrylak Fuchs Gastric
68 Conclusions Checkpoint inhibition therapy demonstrates significant antitumor activity in cisplatin treated metastatic urothelial carcinoma Phase II and III trials are ongoing to confirm initial observations of anti PD-1 and PDL-1 in metastatic urothelial carcinoma A thorough understanding of the markers of resistance and response will help to designing future trials in earlier disease
69
Checkpoint Inibitors for Bladder Cancer
Checkpoint Inibitors for Bladder Cancer Daniel P. Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow Cancer Center,
More informationDisclosure. Astellas. Research funding. Advisory board (to institute) Roche/Genentech Astra Zeneca/Medimmune Astellas
Disclosure Activity Company Research funding Advisory board (to institute) Astellas Roche/Genentech Astra Zeneca/Medimmune Astellas Immunotherapy for urothelial cell carcinoma A NEW HOPE Michiel van der
More informationUpdates in Immunotherapy for Urothelial Carcinoma
Updates in Immunotherapy for Urothelial Carcinoma Andrew J Armstrong MD ScM FACP DUA 2018 Copyright 2006 SciMed. Talk Outline Immunotherapy progress in 2017: 5 new approved PD-1/PD-L1 inhibitory agents
More informationA Giant Leap in the Treatment Options for Advanced Bladder Cancer
A Giant Leap in the Treatment Options for Advanced Bladder Cancer Yohann Loriot, MD, PhD Department of Cancer Medicine & INSERM U981 Gustave Roussy Villejuif, France Clinical Features of Bladder Cancer
More informationOptions for first-line cisplatin-eligible patients
The Past Options for first-line cisplatin-eligible patients Metastatic urothelial cancer Cisplatin-eligible Gemcitabine/ cisplatin MVAC or high-dose intensity MVAC Paclitaxel/ cisplatin/ gemcitabine Bellmunt
More informationAdvanced Bladder Cancer: Check Mate or Check Point Inhibitors
Advanced Bladder Cancer: Check Mate or Check Point Inhibitors Daniel P Petrylak, MD Professor of Medicine and Urology Director, GU Translational Working Group Co Director, Signal Transduction Program Smilow
More informationGenomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy. Raanan Berger MD PhD Sheba Medical Center, Israel
Genomics and Genetics in BC: Precise selection for chemotherapy and Immunotherapy Raanan Berger MD PhD Sheba Medical Center, Israel Disclosures Honoraria, Ad board BMS, MSD, Pfizer, Astra Zeneca, Bayer,
More informationUrothelial Carcinoma Highlights
Urothelial Carcinoma Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano European Association of Urology Research Foundation Disclosures Consulting or Advisory Role: Company:
More informationBiomarkers in Imunotherapy: RNA Signatures as predictive biomarker
Biomarkers in Imunotherapy: RNA Signatures as predictive biomarker Joan Carles, MD PhD Director GU, CNS and Sarcoma Program Department of Medical Oncology Vall d'hebron University Hospital Outline Introduction
More informationUrothelial Cancers- New Strategies. Sandy Srinivas.MD Stanford University
Urothelial Cancers- New Strategies Sandy Srinivas.MD Stanford University Relevant financial relationships in the past twelve months by presenter or spouse/partner. Consultant: Genentech, Astra Zeneca The
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationR&D Conference Call. CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu.
R&D Conference Call CHUGAI PHARMACEUTICAL CO., LTD. Department Manager of Oncology Lifecycle Management Dept. Megumi Uzu July 4, 2016 Forward-Looking Statements This presentation may include forward-looking
More informationAtezolizumab Is a Humanized Anti-PDL1 Antibody That Inhibits the Binding of PD-L1 to PD-1 and B7.1
Phase II, Single-Arm Trial (BIRCH) of Atezolizumab as First-Line or Subsequent Therapy for Locally Advanced or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (NSCLC) Abstract 16LBA Besse B, Johnson
More informationLargos Supervivientes, Tenemos datos?
Largos Supervivientes, Tenemos datos? Javier Puente, MD, PhD Medical Oncology Department. Hospital Clinico San Carlos Associate Professor of Medicine. Complutense University of Madrid. Summary Snapshot
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationThe Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC
The Rationale for Immunotherapy as an Adjuvant Treatment for Locally Advanced BC Seth P. Lerner, MD, FACS Professor, Scott Department of Urology Beth and Dave Swalm Chair in Urologic Oncology Baylor College
More informationIntegrating Immunotherapy into Urologic Oncology: The New Urothelial Cancer Paradigm
Immunotherapy in Urothelial Cancer: Where are We Now & Where are We Going? Arjun Balar, MD Director of Genitourinary Medical Oncology Program NYU Langone Medical Center New York, NY Bladder Cancer Therapeutic
More informationAVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO
AVANCES EN EL TRATAMIENTO DE PRIMERA LINEA EN EL CANCER DE VEJIGA AVANZADO Montse Domènech Althaia, Xarxa Assistencial i Universitària Manresa Urothelial Cancer Therapeutics FDA approved drugs for bladder
More informationTHE SEARCH FOR BIOMARKERS IN BLADDER CANCER
THE SEARCH FOR BIOMARKERS IN BLADDER CANCER CDDP and IO WORLD ALEJO RODRÍGUEZ-VIDA MD PhD Consultant Medical Oncologist Associate Professor Hospital del Mar, Barcelona November 23 rd 2018 DISCLOSURE OF
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More informationMedia Release. Basel, 21 July 2017
Media Release Basel, 21 July 2017 CHMP recommends EU approval for Roche s TECENTRIQ (atezolizumab) in a specific type of metastatic lung and two types of metastatic bladder cancer TECENTRIQ as a potential
More informationIMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER
IMMUNE CHECKPOINT BLOCKADE IN UROTHELIAL CANCER Elizabeth R. Plimack MD MS Director, Genitourinary Clinical Research Associate Professor, Hematology/Oncology Fox Chase Cancer Center, Temple Health Neoadjuvant
More informationImmunotherapy for Genitourinary Cancers
Immunotherapy for Genitourinary Cancers Susan F. Slovin, MD, PhD Genitourinary Oncology Service Sidney Kimmel Center for Prostate and Urologic Cancers Memorial Sloan Kettering Cancer Center New York, New
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationOptimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma. Moran Gadot M.D SHEBA Medical Center ISRAEL
Optimizing treatment for metastatic bladder cancer in chemotherapy-resistant urothelial carcinoma Moran Gadot M.D SHEBA Medical Center ISRAEL Disclosures none All (eligible) patients should get chemotherapy
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationIndication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy
Indication for- and timing of cytoreductive nephrectomy Kidney- and bladder cancer: Immunotherapy Axel Bex, MD, PhD The Netherlands Cancer Institute Oslo, September 4, 2018 Financial and Other Disclosures
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Robert F. Taylor, MD Aurora Health Care
Immunotherapy for the Treatment of Head and Neck Cancers Robert F. Taylor, MD Aurora Health Care Disclosures No relevant financial relationships to disclose I will be discussing non-fda approved indications
More informationImmunotherapy for the Treatment of Kidney and Bladder Cancer
Immunotherapy for the Treatment of Kidney and Bladder Cancer Alan J. Koletsky, MD Genitourinary Cancer Research Program, Lynn Cancer Institute Clinical Asistant Professor of Biomedical Science The Charles
More informationMETRIC Study Key Eligibility Criteria
The METRIC Study METRIC Study Key Eligibility Criteria The pivotal METRIC Study is evaluating glembatumumab vedotin in patients with gpnmb overexpressing metastatic triple-negative breast cancer (TNBC).
More informationRoche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer
Media Release Basel, 22 September 2017 Roche receives EU approval of TECENTRIQ (atezolizumab) in a specific type of metastatic lung cancer and two types of metastatic bladder cancer TECENTRIQ provides
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationCheckpointinhibitoren in der Uro-Onkologie. Carsten Grüllich
Checkpointinhibitoren in der Uro-Onkologie Carsten Grüllich 07.02.15 T-cell Aktivierung und Regulation T cell Costimulation Recognition MHC I Peptide b2m mrna Tumorantigen Tumor Pardoll Nature Rev Cancer
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationBreast Cancer Immunotherapy. Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy
Breast Cancer Immunotherapy Leisha A. Emens, MD PhD Johns Hopkins University Bloomberg Kimmel Institute for Cancer Immunotherapy Conflict of Interest I have the following financial relationships to disclose:
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationPost-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy
Post-ASCO Immunotherapy Highlights (Part 2): Biomarkers for Immunotherapy Lee S. Schwartzberg, MD, FACP Chief, Division of Hematology Oncology; Professor of Medicine, The University of Tennessee; The West
More informationImmunotherapy for the Treatment of Head and Neck Cancers. Barbara Burtness, MD Yale University
Immunotherapy for the Treatment of Head and Neck Cancers Barbara Burtness, MD Yale University Disclosures AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim, Bristol-Myers Squibb, Merck & Co., Inc.,
More informationImmunotherapy, an exciting era!!
Immunotherapy, an exciting era!! Yousef Zakharia MD University of Iowa and Holden Comprehensive Cancer Center Alliance Meeting, Chicago November 2016 Presentation Objectives l General approach to immunotherapy
More informationChallenges in systemic treatment for metastatic bladder cancer. Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University
Challenges in systemic treatment for metastatic bladder cancer Phichai Chansriwong, MD Ramathibodi Hospital, Mahidol University OS PCG 15.8 vs GC 12.7 NS Cisplatin ineligible Second-line chemotherapy
More informationRoche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer
Media Release Basel, 8 January 2016 Roche presents updated results for investigational cancer immunotherapy atezolizumab in advanced bladder cancer Higher expression of PD-L1 (programmed death-ligand 1)
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationTreatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward
Treatment of Advanced Bladder Cancer, Where We've Been and How to Move Forward Maha Hussain, MD, FACP Professor of Medicine & Urology Co-Leader Prostate/GU Oncology Program Associate Director for Clinical
More informationCheckpoint-Inhibitoren beim Lungenkarzinom. Dr. Helge Bischoff Thoraxklinik Heidelberg
Checkpoint-Inhibitoren beim Lungenkarzinom Dr. Helge Bischoff Thoraxklinik Heidelberg Survival (%) First-Line: Polychemotherapy vs 9387 patients 778 patients in studies with platinum chemotherapy 1-year
More informationPresenter Disclosure Information
Presenter Disclosure Information Tara C. Gangadhar, M.D. The following relationships exist related to this presentation: Research funding (Institution): Incyte Corporation and Merck & Co., Inc Preliminary
More informationCancer Drugs Fund. Managed Access Agreement. Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable
Cancer Drugs Fund Managed Access Agreement Atezolizumab for untreated metastatic urothelial cancer where cisplatin is unsuitable NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Cancer Drugs Fund Data
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationEmerging Strategies in Triple-Negative Breast Cancer
Expert Review in Immunotherapy in Breast Cancer Emerging Strategies in Triple-Negative Breast Cancer Reference Slide Deck Is Breast Cancer Immunogenic? Recent proof that breast cancer may elicit an immune
More informationRECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer
RECENT DEVELOPMENTS in Muscle Invasive Bladder Cancer IX CIS and EURASIA ONCOLOGY and RADOLOGY CONGRESS, ONCOUROLOGY SESSION 16 June 2016 Richard E Greenberg, MD, FACS Chief Urologic Oncology, Fox Chase
More informationStructured Immuno-Oncology Combination Strategies To Maximize Efficacy
1 Structured Immuno-Oncology Combination Strategies To Maximize Efficacy Jun Wang MD, PhD Senior Medical Director Immunotherapy Combinations Roche Cancer Immunotherapy Franchise Disclosures Employee of
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationLa revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD
La revolución de la inmunoterapia: dónde la posicionamos? Javier Puente, MD, PhD Hospital Universitario Clinico San Carlos Medical Oncology Department Thoracic & Urological Cancer Unit Complutense University
More informationReflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer
Reflex Testing Guidelines for Immunotherapy in Non-Small Cell Lung Cancer Jimmy Ruiz, MD Assistant Professor Thoracic Oncology Program Wake Forest Comprehensive Cancer Center Disclosures I have no actual
More informationOut of 129 patients with NSCLC treated with Nivolumab in a phase I trial, the OS rate at 5-y was about 16 %, clearly higher than historical rates.
6th Meeting on external quality assessment in molecular pathology, Naples, May 12-13, 2017 Overview of clinical development of checkpoint inhibitors in solid tumors Pr Jaafar BENNOUNA University of Nantes
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationNeoplasie uroteliali 2017 Highlights. Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
Neoplasie uroteliali 2017 Highlights Andrea Necchi Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy Disclosures Consulting or Advisory Role: Company: Roche, Bayer, Merck & Co. Inc., Astra
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationSupplementary Online Content
Supplementary Online Content Powles T, O Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 openlabel
More informationDevelopment of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
Gong et al. Journal for ImmunoTherapy of Cancer (2018) 6:8 DOI 10.1186/s40425-018-0316-z REVIEW Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationPost-ASCO 2017 Cancer du sein Triple Négatif
Post-ASCO 217 Cancer du sein Triple Négatif A.Ladjeroud, K.Bouzid Centre Pierre et Marie Curie- Alger Oran, 3 Septembre 217 Phase III Investigation of Neoadjuvant Carboplatin ± Veliparib in Combination
More informationEnterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation
Enterprise Interest Lecture 9º Personalized Healthcare in Oncology sponsored by Roche, Lisbon 2017 Bladder Diagnostic Advisory Board Invitation sponsored by Astra-Zeneca, London 2017 SPEC-02 ESP/ESMO PD-L1
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationPembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-028 Study
Pembrolizumab for Patients With PD-L1 Positive Advanced Carcinoid or Pancreatic Neuroendocrine Tumors: Results From the KEYNOTE-28 Study Abstract 427O Mehnert JM, Bergsland E, O Neil BH, Santoro A, Schellens
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationTreatment of muscle invasive bladder cancer. ie: pt2. N. Mottet
Treatment of muscle invasive bladder cancer ie: pt2 N. Mottet Disclosures Astellas BMS Pierre Fabre Sanofi MIBC: really undertreated 28 691 MIBC in the US (national database). Gray Eur Urol 2013 Patients
More informationEvolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents
Evolving Paradigms in HER2+ MBC: Strategies for Individualizing Therapy with Available Agents Kimberly L. Blackwell MD Professor Department of Medicine and Radiation Oncology Duke University Medical Center
More informationLa realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga
La realidad de la inmunoterapia en el tratamiento de 1ª y 2ª línea del cáncer de vejiga Daniel Castellano Oncología Médica. Unidad de Tumores Genito-Urinarios Hospital Universitario 12 de Octubre. I +
More informationImmunotherapy for Breast Cancer Clinical Development
Immunotherapy for Breast Cancer Clinical Development Laurence Buisseret, MD, PhD Breast Cancer Translational Research Laboratory Institut Jules Bordet Université Libre de Bruxelles (ULB) ESMO preceptorship
More informationCENTENE PHARMACY AND THERAPEUTICS DRUG REVIEW 3Q17 April May
BRAND NAME Keytruda GENERIC NAME Pembrolizumab MANUFACTURER Merck & Co., Inc. DATE OF APPROVAL Non-small cell lung cancer (NSCLC) indication: May 10, 2017 Urothelial carcinoma indication: May 18, 2017
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationUROTHELIAL CELL CANCER
UROTHELIAL CELL CANCER Indications and regimens for neoadjuvant systemic treatment Astrid A. M. van der Veldt, MD, PhD, medical oncologist Department of Medical Oncology Erasmus Medical Center Cancer Institute
More informationESMO Preceptorship Breast Cancer. Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia
ESMO Preceptorship Breast Cancer Giuseppe Curigliano MD, PhD Breast Cancer Program Division of Early Drug Development Istituto Europeo di Oncologia Outline Rational for immune-based therapy in BC How to
More informationRecent advances in the management of metastatic breast cancer in older adults
Recent advances in the management of metastatic breast cancer in older adults Laura Biganzoli Medical Oncology Dept New Hospital of Prato Istituto Toscano Tumori Italy Important recent advances in the
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationpatients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease
patients who have received multiple lines of prior chemotherapy including a platinum-containing regimen patients without formal measurable disease First, perc agreed with CGP that the diagnosis of urothelial
More informationI Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena
I Tumori della Vescica Inquadramento clinico Roberto Sabbatini Azienda Ospedaliero Universitaria Policlinico di Modena XII Corso di aggiornamento AIRTUM per operatori dei Registri Tumori Reggio Emilia
More informationPredictive Biomarkers for Pembrolizumab. Eric H. Rubin, M.D.
Predictive Biomarkers for Pembrolizumab Eric H. Rubin, M.D. PD-1 and PD-L1/L2 Pathway PD-1 is an immune checkpoint receptor Binding of PD-1 by its ligands PD-L1 or PD-L2 leads to downregulation of T-cell
More informationImmunoconjugates in Both the Adjuvant and Metastatic Setting
Immunoconjugates in Both the Adjuvant and Metastatic Setting Mark Pegram, M.D. Director, Stanford Breast Oncology Program Co-Director, Molecular Therapeutics Program Trastuzumab Treatment of Breast Tumor
More informationCancer Immunotherapy Patient Forum. for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015
Cancer Immunotherapy Patient Forum for the Treatment of Melanoma, Leukemia, Lymphoma, Lung and Genitourinary Cancers - November 7, 2015 Biomarkers and Patient Selection Julie R. Brahmer, M.D. Director
More informationPolicy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016
Name of Policy: Tecentriq (Atezolizumab) Policy #: 668 Effective Date: December 1, 2016 Category: Pharmacology Latest Review Date: September 2016 Background/Definitions: As a general rule, benefits are
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationUse of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies. Eric H. Rubin, MD Merck Research Laboratories
Use of Single-Arm Cohorts/Trials to Demonstrate Clinical Benefit for Breakthrough Therapies Eric H. Rubin, MD Merck Research Laboratories Outline Pembrolizumab P001 study - example of multiple expansion
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationDevelopping the next generation of studies in RCC
Developping the next generation of studies in RCC Bernard Escudier Institut Gustave Roussy Villejuif, France Disclosure Information Advisory/Consultancy Role Pfizer, Exelixis, Novartis, BMS, Bayer, Roche,
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationImmunotherapy and urothelial carcinoma. Yohann Loriot
Immunotherapy and urothelial carcinoma Yohann Loriot Immunothérapie en clinique : Cancers de vessie Où en sommes nous? Données phase I/II FDA «breakthrough designation» Prochaines étapes? Immunothérapie
More informationKarcinom dojke. PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski
Karcinom dojke PANEL: Semir Bešlija, Zdenka Gojković, Robert Šeparović, Tajana Silovski MBC: HER2 PHEREXA: Study Design Multicenter, randomized, open-label phase III trial Stratified by prior CNS disease,
More informationMolecular Targets in Bladder Cancer: PD-1 and Beyond
Molecular Targets in Bladder Cancer: PD-1 and Beyond Sumanta Kumar Pal, M.D. Assistant Professor, Department of Medical Oncology & Experimental Therapeutics Co-Director, Kidney Cancer Program City of Hope
More informationImmunotherapy in Patients with Non-Small Cell Lung Cancer
LIVE WEBINARS Immunotherapy in Patients with Non-Small Cell Lung Cancer Presented by: Leora Horn, MD, MSc Vanderbilt-Ingram Cancer Center July 14, 216 Moderated by Rose K. Joyce NCCN, Conferences and Meetings
More information